pharmaceuticals

Pfizer Inc. (NYSE:PFE) has recently launched a multi-year cost reduction initiative aimed at saving approximately $1.5 billion by the end of 2027. This new program builds upon a $4 billion cost reduction plan announced last year. The move came as the pharmaceutical giant faces declining investor...

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are rising in Thursday’s after-hours session following the company’s first-quarter financial results. Q1 Earnings: Recursion reported first-quarter revenue of $13.491 million, which beat analyst estimates of $12.65 million, according to...

Allarity Therapeutics Inc (NASDAQ:ALLR) shares are trading higher on a strong session volume of 67 million, as per the data from Benzinga Pro. The company announced the early discontinuation of its Phase 2 clinical trial of stenoparib for advanced recurrent ovarian cancer....

The Federal Trade Commission (FTC) is intensifying its efforts to challenge numerous pharmaceutical patent listings, aiming to facilitate the availability of more affordable alternatives to brand-name drugs, including blockbusters like Novo Nordisk A/S’s (NYSE:NVO) Ozempic...

Intra-Cellular Therapies Inc (NASDAQ:ITCI) unveiled on Tuesday topline results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD).  Topline results from the second Phase 3 study, Study 502, are anticipated...

On Wednesday, key U.S. stock indexes closed lower, as the Dow Jones Industrial Average fell by 1.1% to 38,461.51, the S&P 500 dropped nearly 1% to 5,160.64, and the Nasdaq ended the day down by 0.8% at 16,170.36. These are the top stocks that gained the attention of retail traders and investors...

GoodRx Holdings Inc (NASDAQ: GDRX) got an upgrade last month from Wells Fargo analyst. Despite being a “re-accelerating high-growth, high-margin company,” the stock was trading at a discount both to its peers and its historical average, according to KeyBanc Capital Markets. The GoodRx...

In a massive stride towards Alzheimer’s treatment, IGC Pharma (NYSE:IGC) recently revealed promising interim results for their pioneering drug, IGC-AD1, aimed at mitigating agitation in Alzheimer’s patients. This breakthrough is a beacon of hope for millions affected by this...

The FDA granted accelerated approval on Thursday to Madrigal Pharmaceuticals Inc.’s (NASDAQ:MDGL) Rezdiffra (resmetirom) noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis) to be used along with diet and exercise.  Continued...

The World Health Organization (WHO) released its latest HIV Drug Resistance (HIVDR) Report, shedding light on the growing areas of drug resistance and providing crucial recommendations for countries to navigate potential challenges.  The report carried both optimistic and concerning...

CASI Pharmaceuticals Inc (NASDAQ:CASI) and BioInvent International AB announced preliminary efficacy data for BI-1206 in combination with rituximab in patients with relapsed/refractory (R/R) indolent Non-Hodgkin’s Lymphoma (iNHL) in the ongoing development program in China. The...

The news was trumpeted around the world: Germany, the European Union’s largest economy, surprised the global cannabis industry with the announcement of the legalization of cannabis for restricted recreational use, to be effective April 1. Additional regulations for collective private...

Pfizer Inc. (NYSE: PFE) recently held its fourth-quarter earnings call, revealing a year of contrasts for the pharmaceutical giant. While the company faced setbacks, particularly with its COVID-19 products, it also made significant strides in other areas, setting a foundation for future growth. The...

On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine Gardasil. However, Merck still recorded a net quarterly loss due to...

Biogen Inc (NASDAQ:BIIB) is pulling the plug on its Aduhelm Alzheimer’s disease drug more than two years after the drug came into the limelight after receiving controversial FDA approval. Biogen said on Wednesday it would discontinue developing and commercializing Aduhelm (aducanumab-avwa)...